Cases & Deals

The Regents of the University of California establishes patent portfolio related to anti-CD22 antibodies for the treatment of B cell malignancies

Clients Regents of the University of California, The

Jones Day assisted the Regents of the University of California in the development of a global patent portfolio related to uses of CD22 antibodies for the treatment of B cell malignancies, such as non-Hodgkin's lymphoma (NHL).

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.